Dr Lal Pathlabs Ltd (LALPATHLAB) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1000163,
    "name": "Dr Lal Pathlabs",
    "stock_name": "Dr Lal Pathlabs",
    "full_name": "Dr Lal Pathlabs Ltd",
    "name_url": "stocks-analysis/dr-lal-pathlabs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "3,016.40",
    "chg": -38.05,
    "chgp": "-1.25%",
    "dir": -1,
    "prev_price": "3,054.45",
    "mcapval": "25,270.04 Cr",
    "mcap": "Small Cap",
    "scripcode": 539524,
    "symbol": "LALPATHLAB",
    "ind_name": "Healthcare Services",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE600L01024",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "51.57 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-lal-pathlabs-1000163-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Dr Lal Pathlabs Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-lal-pathlabs-technical-momentum-shifts-amid-mixed-indicator-signals-3740291",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/DrLalPathlabs_technicaldot_3740291.png",
        "date": "2025-12-02 08:10:30",
        "description": "Dr Lal Pathlabs has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This change is reflected in a variety of technical indicators, including moving averages and momentum oscillators, which present a nuanced picture of the stock’s near-term trajectory within the healthcare services sector."
      },
      {
        "title": "Dr Lal Pathlabs Technical Momentum Shifts Amid Sideways Market Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-lal-pathlabs-technical-momentum-shifts-amid-sideways-trend-3737528",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/DrLalPathlabs_technicaldot_3737528.png",
        "date": "2025-12-01 08:04:25",
        "description": "Dr Lal Pathlabs has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more sideways trend. This change is reflected across key technical indicators including MACD, RSI, and moving averages, signalling a period of consolidation for the healthcare services company amid broader market fluctuations."
      },
      {
        "title": "Dr Lal Pathlabs Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-lal-pathlabs-downgraded-to-hold-by-marketsmojo-amid-valuation-concerns-3730744",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/DrLalPathlabs_mojoScore_3730744.png",
        "date": "2025-11-26 09:46:59",
        "description": "Dr Lal Pathlabs has experienced a revision in its market evaluation, reflecting a nuanced shift in its financial and technical outlook. This adjustment comes amid a backdrop of strong operational metrics tempered by valuation concerns and evolving market sentiment."
      },
      {
        "title": "Dr Lal Pathlabs Adjusts Quality Grade Amidst Strong Financial Metrics and Promoter Stake Changes",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-lal-pathlabs-stock-rating-downgraded-from-buy-to-hold-3669949",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/DrLalPathlabs_mojoScore_3669949.png",
        "date": "2025-11-04 09:01:15",
        "description": "Dr Lal Pathlabs has experienced a change in its quality grade, now rated as good. The company has shown strong financial metrics, including significant sales and EBIT growth, a solid balance sheet, and high management efficiency. However, its long-term growth outlook appears more modest, with a slight reduction in promoter stake."
      },
      {
        "title": "Dr. Lal Pathlabs Receives Quality Grade Upgrade Amid Strong Financial Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-lal-pathlabs-quality-grade-downgraded-from-excellent-to-good-amid-strong-financial-metrics-3668610",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/DrLalPathlabs_qualitydot_3668610.png",
        "date": "2025-11-04 08:00:13",
        "description": "Dr. Lal Pathlabs has recently revised its evaluation, showcasing strong sales growth of 14.39% and EBIT growth of 19.92% over five years. The company boasts a solid balance sheet with no debt, high returns on capital and equity, and a competitive institutional holding, reinforcing its market position."
      },
      {
        "title": "How has been the historical performance of Dr Lal Pathlabs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-dr-lal-pathlabs-3668141",
        "imagepath": "",
        "date": "2025-11-03 22:52:28",
        "description": "Answer:\nThe historical performance of Dr Lal Pathlabs shows a consistent growth trajectory in net sales and profits over the years, with significant increases noted in the latest fiscal year ending March 2025.\n\nBreakdown:\nDr Lal Pathlabs has demonstrated robust growth in net sales, rising from 1,203.40 Cr in March 2019 to 2,461.40 Cr in March 2025. The total operating income followed a similar upward trend, reaching 2,461.40 Cr in March 2025, up from 1,203.40 Cr in March 2019. Operating profit, excluding other income, also increased significantly, from 343.60 Cr in March 2020 to 695.50 Cr in March 2025. The profit before tax saw a substantial rise from 300.60 Cr in March 2019 to 624.70 Cr in March 2025, while profit after tax increased from 200.50 Cr to 492.20 Cr in the same period. The company's earnings per share (EPS) improved markedly from 23.91 in March 2019 to 58.27 in March 2025, reflecting enhanced ..."
      },
      {
        "title": "How has been the historical performance of Dr Lal Pathlabs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-dr-lal-pathlabs-3662784",
        "imagepath": "",
        "date": "2025-10-31 22:41:19",
        "description": "Answer:\nThe historical performance of Dr Lal Pathlabs shows a consistent growth trend in net sales and profits over the years.\n\nBreakdown:\nDr Lal Pathlabs has demonstrated significant growth in net sales, increasing from INR 1,203.40 crore in March 2019 to INR 2,461.40 crore in March 2025. The total operating income followed a similar trajectory, reaching INR 2,461.40 crore in March 2025, up from INR 1,203.40 crore in March 2019. Operating profit (PBDIT) also rose notably, from INR 339.60 crore in March 2019 to INR 788.90 crore in March 2025, reflecting an improvement in operating profit margin from 24.4% to 28.26%. Profit before tax increased from INR 300.60 crore in March 2019 to INR 624.70 crore in March 2025, while profit after tax surged from INR 200.50 crore to INR 492.20 crore during the same period. The company's total assets grew from INR 1,351.46 crore in March 2020 to INR 2,630.17 crore in March ..."
      },
      {
        "title": "Are Dr Lal Pathlabs latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-dr-lal-pathlabs-latest-results-good-or-bad-3662382",
        "imagepath": "",
        "date": "2025-10-31 19:17:46",
        "description": "Dr Lal PathLabs has reported strong financial results for the quarter ended September 2025. The company achieved record revenue of ₹730.60 crores, reflecting a year-on-year growth of 10.66% compared to ₹660.20 crores in the same quarter last year. This performance underscores the company's ability to maintain robust demand for its diagnostic services and successful execution of its network expansion initiatives.\n\nThe consolidated net profit for the quarter reached ₹150.40 crores, which represents a year-on-year increase of 16.41% from ₹129.20 crores in the previous year. Additionally, the operating profit before depreciation, interest, and tax (PBDIT) stood at ₹224.10 crores, marking a 10.67% increase from the prior year, with operating margins remaining stable at 30.67%.\n\nThe company has demonstrated operational efficiency, as evidenced by the net profit margin expanding to 20.83%, up 102 basis points from..."
      },
      {
        "title": "Dr Lal PathLabs Q2 FY26: Strong Momentum with 16% Profit Growth Despite Premium Valuation",
        "link": "https://www.marketsmojo.com/news/result-analysis/dr-lal-pathlabs-q2-fy26-strong-momentum-with-16-profit-growth-despite-premium-valuation-3662324",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/DrLalPathlabs_quaterlyResult_3662324.png",
        "date": "2025-10-31 17:47:08",
        "description": "Dr Lal PathLabs Ltd., one of India's leading diagnostic services providers, delivered a robust performance in Q2 FY26, with consolidated net profit surging 16.41% year-on-year to ₹150.40 crores, demonstrating strong operational momentum in the diagnostic services sector. The company's market capitalisation stands at ₹25,761 crores, with shares trading at ₹3,136.10 as of October 31, 2025, up 1.52% following the results announcement."
      }
    ],
    "total": 258,
    "sid": "1000163",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-lal-pathlabs-1000163"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "26-Nov-2025",
      "details": "Attached",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "13-Nov-2025",
      "details": "Attached",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "08-Nov-2025",
      "details": "Attached",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Lal Pathlabs Ltd has declared <strong>70%</strong> dividend, ex-date: 07 Nov 25",
          "dt": "2025-11-07",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Dr Lal Pathlabs Technical Momentum Shifts Amid Mixed Market Signals

2025-12-02 08:10:30

Dr Lal Pathlabs has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This change is reflected in a variety of technical indicators, including moving averages and momentum oscillators, which present a nuanced picture of the stock’s near-term trajectory within the healthcare services sector.

Dr Lal Pathlabs Technical Momentum Shifts Amid Sideways Market Trend

2025-12-01 08:04:25

Dr Lal Pathlabs has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more sideways trend. This change is reflected across key technical indicators including MACD, RSI, and moving averages, signalling a period of consolidation for the healthcare services company amid broader market fluctuations.

Dr Lal Pathlabs Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-11-26 09:46:59

Dr Lal Pathlabs has experienced a revision in its market evaluation, reflecting a nuanced shift in its financial and technical outlook. This adjustment comes amid a backdrop of strong operational metrics tempered by valuation concerns and evolving market sentiment.

Dr Lal Pathlabs Adjusts Quality Grade Amidst Strong Financial Metrics and Promoter Stake Changes

2025-11-04 09:01:15

Dr Lal Pathlabs has experienced a change in its quality grade, now rated as good. The company has shown strong financial metrics, including significant sales and EBIT growth, a solid balance sheet, and high management efficiency. However, its long-term growth outlook appears more modest, with a slight reduction in promoter stake.

Dr. Lal Pathlabs Receives Quality Grade Upgrade Amid Strong Financial Performance

2025-11-04 08:00:13

Dr. Lal Pathlabs has recently revised its evaluation, showcasing strong sales growth of 14.39% and EBIT growth of 19.92% over five years. The company boasts a solid balance sheet with no debt, high returns on capital and equity, and a competitive institutional holding, reinforcing its market position.

How has been the historical performance of Dr Lal Pathlabs?

2025-11-03 22:52:28

Answer: The historical performance of Dr Lal Pathlabs shows a consistent growth trajectory in net sales and profits over the years, with significant increases noted in the latest fiscal year ending March 2025. Breakdown: Dr Lal Pathlabs has demonstrated robust growth in net sales, rising from 1,203.40 Cr in March 2019 to 2,461.40 Cr in March 2025. The total operating income followed a similar upward trend, reaching 2,461.40 Cr in March 2025, up from 1,203.40 Cr in March 2019. Operating profit, excluding other income, also increased significantly, from 343.60 Cr in March 2020 to 695.50 Cr in March 2025. The profit before tax saw a substantial rise from 300.60 Cr in March 2019 to 624.70 Cr in March 2025, while profit after tax increased from 200.50 Cr to 492.20 Cr in the same period. The company's earnings per share (EPS) improved markedly from 23.91 in March 2019 to 58.27 in March 2025, reflecting enhanced ...

How has been the historical performance of Dr Lal Pathlabs?

2025-10-31 22:41:19

Answer: The historical performance of Dr Lal Pathlabs shows a consistent growth trend in net sales and profits over the years. Breakdown: Dr Lal Pathlabs has demonstrated significant growth in net sales, increasing from INR 1,203.40 crore in March 2019 to INR 2,461.40 crore in March 2025. The total operating income followed a similar trajectory, reaching INR 2,461.40 crore in March 2025, up from INR 1,203.40 crore in March 2019. Operating profit (PBDIT) also rose notably, from INR 339.60 crore in March 2019 to INR 788.90 crore in March 2025, reflecting an improvement in operating profit margin from 24.4% to 28.26%. Profit before tax increased from INR 300.60 crore in March 2019 to INR 624.70 crore in March 2025, while profit after tax surged from INR 200.50 crore to INR 492.20 crore during the same period. The company's total assets grew from INR 1,351.46 crore in March 2020 to INR 2,630.17 crore in March ...

Are Dr Lal Pathlabs latest results good or bad?

2025-10-31 19:17:46

Dr Lal PathLabs has reported strong financial results for the quarter ended September 2025. The company achieved record revenue of ₹730.60 crores, reflecting a year-on-year growth of 10.66% compared to ₹660.20 crores in the same quarter last year. This performance underscores the company's ability to maintain robust demand for its diagnostic services and successful execution of its network expansion initiatives. The consolidated net profit for the quarter reached ₹150.40 crores, which represents a year-on-year increase of 16.41% from ₹129.20 crores in the previous year. Additionally, the operating profit before depreciation, interest, and tax (PBDIT) stood at ₹224.10 crores, marking a 10.67% increase from the prior year, with operating margins remaining stable at 30.67%. The company has demonstrated operational efficiency, as evidenced by the net profit margin expanding to 20.83%, up 102 basis points from...

Dr Lal PathLabs Q2 FY26: Strong Momentum with 16% Profit Growth Despite Premium Valuation

2025-10-31 17:47:08

Dr Lal PathLabs Ltd., one of India's leading diagnostic services providers, delivered a robust performance in Q2 FY26, with consolidated net profit surging 16.41% year-on-year to ₹150.40 crores, demonstrating strong operational momentum in the diagnostic services sector. The company's market capitalisation stands at ₹25,761 crores, with shares trading at ₹3,136.10 as of October 31, 2025, up 1.52% following the results announcement.

View All News